Niacin’s Immune Modulation: A New Frontier in Glioblastoma Therapy
A phase I dose-escalation clinical trial investigated the effects of niacin on immune responses in patients with newly diagnosed glioblastoma. The study, published in Neurology Neuroimmunology & Neuroinflammation, explores how this common B vitamin can modulate the body’s immune system in the context of a highly aggressive brain tumor. While the full results are pending, the trial represents a novel approach to harnessing metabolic pathways to influence neuroinflammation and the tumor microenvironment.
Why it might matter to you:
This research directly intersects with neuroimmunology, demonstrating how systemic metabolic interventions can target brain-specific inflammation. For a researcher in neurodevelopmental disorders, understanding how immune modulation affects neural outcomes is crucial. The trial’s focus on a safe, repurposed compound like niacin could inform future strategies for modulating neuroinflammation in developmental contexts, offering a potential bridge between oncology and neurodevelopmental therapeutics.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
